Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study

Rottenburger, Christof; Nicolas, Guillaume P.; McDougall, Lisa; Kaul, Felix; Cachovan, Michal; Vija, A. Hans; Schibli, Roger; Geistlich, Susanne; Schumann, Anne; Rau, Tilman; Glatz, Katharina; Behe, Martin; Christ, Emanuel R.; Wild, Damian

doi:10.2967/jnumed.119.233031

Metadata only

Autor(in)

Rottenburger, Christof

Nicolas, Guillaume P.

Datum

2020-04

Typ

Journal Article

Zitate

63 Zitate in Scopus

ETH Bibliographie

yes

Altmetrics

Publikationsstatus

published

Externe Links

https://doi.org/10.2967/jnumed.119.233031

Zeitschrift / Serie

The Journal of Nuclear Medicine

Band

61(4)

Seiten / Artikelnummer

520 - 526

Verlag

Society of Nuclear Medicine

Thema

cholecystokinin 2 receptor targeting; peptide receptorradionuclide therapy; 177Lu-PP-F11N; theranostics

Organisationseinheit

03688 - Schibli, Roger / Schibli, Roger
03688 - Schibli, Roger / Schibli, Roger

Mehr

Alle Metadaten anzeigen

Zitate

63 Zitate in Scopus

ETH Bibliographie

yes

Altmetrics

Research Collection

Suche

Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study Mendeley CSV RIS BibTeX

Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study

Mendeley

CSV

RIS

BibTeX